Wilms’ tumor 1 silencing decreases the viability and chemoresistance of glioblastoma cells in vitro: a potential role for IGF-1R de-repression
- 4 September 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Neuro-Oncology
- Vol. 103 (1), 87-102
- https://doi.org/10.1007/s11060-010-0374-7
Abstract
Wilms’ tumor 1 (WT1) is a transcription factor with a multitude of downstream targets that have wide-ranging effects in non-glioma cell lines. Though its expression in glioblastomas is now well-documented, the role of WT1 in these tumors remains poorly defined. We hypothesized that WT1 functions as an oncogene to enhance glioblastoma viability and chemoresistance. WT1’s role was examined by studying the effect of WT1 silencing and overexpression on DNA damage, apoptosis and cell viability. Results indicated that WT1 silencing adversely affected glioblastoma viability, at times, in synergy with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and cisplatin. To investigate other mechanisms through which WT1 could affect viability, we measured cell cycle distribution, senescence, and autophagy. WT1 silencing had no effect on these processes. Lastly, we examined WT1 regulation of IGF-1R expression. Counterintuitively, upregulation of IGF-1R was evident after WT1 silencing. In conclusion, WT1 functions as a survival factor in glioblastomas, possibly through inhibition of IGF-1R expression.Keywords
This publication has 82 references indexed in Scilit:
- The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiformeNeuro-Oncology, 2007
- WT1 Influences Apoptosis Through Transcriptional Regulation of Bcl-2 Family MembersCell Cycle, 2006
- Paraptosis: mediation by MAP kinases and inhibition by AIP-1/AlixCell Death & Differentiation, 2004
- WT1-p53 Interactions in Insulin-like Growth Factor-I Receptor Gene RegulationPublished by Elsevier BV ,2003
- Enhanced radiosensitivity of malignant glioma cells after adenoviral p53 transductionJournal of Neurosurgery, 1999
- Regulation of Insulin-Like Growth Factor I Receptor Promoter Activity by Wild-Type and Mutant Versions of the WT1 Tumor SuppressorEndocrinology, 1999
- Oncogenic Ras triggers cell suicide through the activation of a caspase-independent cell death program in human cancer cellsOncogene, 1999
- Expression of the Wilms' Tumor Gene WT1 in Solid Tumors and Its Involvement in Tumor Cell GrowthJapanese Journal of Cancer Research, 1999
- Descriptive epidemiology of primary brain and CNS tumors: Results from the Central Brain Tumor Registry of the United States, 1990-1994Neuro-Oncology, 1999
- WT-1 is required for early kidney developmentCell, 1993